Jordan E Cates1,2, Avnika B Amin3, Jacqueline E Tate1, Ben Lopman3, Umesh Parashar1. 1. From the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA. 2. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA. 3. Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA.
Abstract
BACKGROUND: Rotavirus causes 215,000 deaths from severe childhood diarrhea annually. Concerns exist that a monovalent vaccine (RV1) and a pentavalent vaccine (RV5) may be less effective against rotavirus strains not contained in the vaccines. We estimated the vaccine effectiveness (VE) of RV1 and RV5 against severe rotavirus gastroenteritis caused by vaccine (homotypic) and nonvaccine (partially and fully heterotypic) strains. METHODS: After conducting a systematic review, we meta-analyzed 31 case-control studies (N = 27,293) conducted between 2006 and 2020 using a random-effects regression model. RESULTS: In high-income countries, RV1 VE was 10% lower against partially heterotypic (P = 0.04) and fully heterotypic (P = 0.10) compared with homotypic strains (homotypic VE: 90% [95% confidence intervals (CI): 82-94]; partially heterotypic VE: 79% [95% CI: 71-85]; fully heterotypic VE: 80% [95% CI: 65-88]). In middle-income countries, RV1 VE was 14-16% lower against partially heterotypic (P = 0.06) and fully heterotypic (P = 0.04) compared with homotypic strains (homotypic VE: 81% [95% CI: 69-88]; partially heterotypic VE: 67% [95% CI: 54-76]; fully heterotypic VE: 65% [95% CI: 51-75]). Strain-specific RV5 VE differences were less pronounced, and primarily derived from high-income countries. Limited data were available from low-income countries. CONCLUSIONS: Vaccine effectiveness of RV1 and RV5 was somewhat lower against nonvaccine than vaccine strains. Ongoing surveillance is important to continue long-term monitoring for strain replacement, particularly in low-income settings where data are limited.
BACKGROUND: Rotavirus causes 215,000 deaths from severe childhood diarrhea annually. Concerns exist that a monovalent vaccine (RV1) and a pentavalent vaccine (RV5) may be less effective against rotavirus strains not contained in the vaccines. We estimated the vaccine effectiveness (VE) of RV1 and RV5 against severe rotavirus gastroenteritis caused by vaccine (homotypic) and nonvaccine (partially and fully heterotypic) strains. METHODS: After conducting a systematic review, we meta-analyzed 31 case-control studies (N = 27,293) conducted between 2006 and 2020 using a random-effects regression model. RESULTS: In high-income countries, RV1 VE was 10% lower against partially heterotypic (P = 0.04) and fully heterotypic (P = 0.10) compared with homotypic strains (homotypic VE: 90% [95% confidence intervals (CI): 82-94]; partially heterotypic VE: 79% [95% CI: 71-85]; fully heterotypic VE: 80% [95% CI: 65-88]). In middle-income countries, RV1 VE was 14-16% lower against partially heterotypic (P = 0.06) and fully heterotypic (P = 0.04) compared with homotypic strains (homotypic VE: 81% [95% CI: 69-88]; partially heterotypic VE: 67% [95% CI: 54-76]; fully heterotypic VE: 65% [95% CI: 51-75]). Strain-specific RV5 VE differences were less pronounced, and primarily derived from high-income countries. Limited data were available from low-income countries. CONCLUSIONS: Vaccine effectiveness of RV1 and RV5 was somewhat lower against nonvaccine than vaccine strains. Ongoing surveillance is important to continue long-term monitoring for strain replacement, particularly in low-income settings where data are limited.
Authors: Paul A Gastañaduy; Ingrid Contreras-Roldán; Chris Bernart; Beatriz López; Stephen R Benoit; Marvin Xuya; Fredy Muñoz; Rishi Desai; Osbourne Quaye; Ka Ian Tam; Diana K Evans-Bowen; Umesh D Parashar; Manish Patel; John P McCracken Journal: Clin Infect Dis Date: 2016-05-01 Impact factor: 9.079
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Ricardo G Gurgel; Anna K Bohland; Sarah C F Vieira; Débora M P Oliveira; Paula B Fontes; Viviane F Barros; Marcela F Ramos; Winifred Dove; Toyoko Nakagomi; Osamu Nakagomi; Jailson B Correia; Nigel Cunliffe; Luis E Cuevas Journal: Gastroenterology Date: 2009-07-24 Impact factor: 22.682
Authors: Mary Allen Staat; Daniel C Payne; Stephanie Donauer; Geoffrey A Weinberg; Kathryn M Edwards; Peter G Szilagyi; Marie R Griffin; Caroline B Hall; Aaron T Curns; Jon R Gentsch; Shelia Salisbury; Gerry Fairbrother; Umesh D Parashar Journal: Pediatrics Date: 2011-07-18 Impact factor: 7.124
Authors: Tessa Braeckman; Koen Van Herck; Nadia Meyer; Jean-Yves Pirçon; Montse Soriano-Gabarró; Elisabeth Heylen; Mark Zeller; Myriam Azou; Heidi Capiau; Jan De Koster; Anne-Sophie Maernoudt; Marc Raes; Lutgard Verdonck; Marc Verghote; Anne Vergison; Jelle Matthijnssens; Marc Van Ranst; Pierre Van Damme Journal: BMJ Date: 2012-08-08
Authors: Mentor Ali Ber Lucien; Mathew D Esona; Manise Pierre; Gerard Joseph; Chedelène Rivière; Eyal Leshem; Negar Aliabadi; Anne Marie Desormeaux; Jocelyn Andre-Alboth; David L Fitter; Yoran Grant-Greene; Jacqueline Tate; Jacques Boncy; Roopal Patel; Eleanor Burnett; Stanley Juin; Umesh D Parashar; Michael D Bowen Journal: IJID Reg Date: 2022-07-14
Authors: Assucênio Chissaque; Rachel M Burke; Esperança L Guimarães; Filomena Manjate; Arsénio Nhacolo; Jorfélia Chilaúle; Benilde Munlela; Percina Chirinda; Jerónimo S Langa; Idalécia Cossa-Moiane; Elda Anapakala; Adilson Fernando Loforte Bauhofer; Marcelino Garrine; Eva D João; Júlia Sambo; Luzia Gonçalves; Goitom Weldegebriel; Keith Shaba; Isah Mohammed Bello; Jason M Mwenda; Umesh D Parashar; Jacqueline E Tate; Inácio Mandomando; Nilsa de Deus Journal: Vaccines (Basel) Date: 2022-03-15